A clinical case of new onset type 2 diabetes mellitus in a patient with coronary artery disease and obesity treated with atorvastatin
Aim. To improve diagnosis and treatment of patients with coronary artery disease and obesity.
Material and methods. New onset diabetes mellitus in patient with coronary artery disease and comorbid obesity 6 months after atorvastatin treatment was described.
Results and Discussion. In our observation, the patient K. as of 11.07.16 was diagnosed with: Сoronary artery disease, Stable angina pectoris III, post-infarction (08.04.2016) cardiosclerosis. Planned stenting of of the second branch of the right coronary artery with stenosis of 99%. 17.05.16. Stage 1 hypertension, degree III, risk 4 (very high). Hypertensive heart. Heart failure IIA with preserved ejection fraction. Obesity class I, abdominal type. The patient had initial disorders of the glucose metabolism, such as hyperglycemia, insulin resistance, hyperleptinemia, and decreased omentine levels. The patient was treated with atorvastatin 40 mg according to treatment guidelines. New onset diabetes mellitus in the patient was diagnosed six months later and Metformin 500 mg was prescribed. Thus, as a result of timely diagnosed type 2 diabetes, it was possible to prescribe necessary treatment and avoid complications.
Conclusion. Patients with coronary artery disease and obesity are at increased risk of developing type 2 diabetes, which requires more medical attention and glucose metabolism monitoring.
Brault M., Ray J., Gomes Y.H. : Statin treatment and new-onset diabetes: a revive of proposed mechanisms Metabolism. 2014, 63(6). 735 - 745. https://doi.org/10.1016/j.metabol.2014.02.014
Cederberg H., Stancakova А., Yaluri N. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up stady of the METSIM cohort. Diabetol. 2015, 5, 109-117.
Eman M.Alissa, Maisa'a M.Al-Salmi, Nabeel A.Alama, Gordon A.Ferns: Role of omentin-1 and C-reactive protein in obese subjects with subclinical inflamation. Journal of Clinical and Translational Endocrinology.2016.3.7-11
Saklayen MG: The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018.20(2).12.
This work is licensed under a Creative Commons Attribution 4.0 International License.